Eiger Biopharmaceutica Cash And Equivalents vs. Revenue
| EIGRDelisted Stock | USD 0.74 0.03 3.90% |
For Eiger Biopharmaceutica profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Eiger Biopharmaceutica to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Eiger Biopharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Eiger Biopharmaceutica's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Eiger Biopharmaceuticals over time as well as its relative position and ranking within its peers.
Eiger |
Eiger Biopharmaceuticals Revenue vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Eiger Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Eiger Biopharmaceutica value to that of its competitors to determine the firm's financial worth. Eiger Biopharmaceuticals is rated below average in cash and equivalents category among its peers. It is rated # 5 in revenue category among its peers totaling about 0.11 of Revenue per Cash And Equivalents. The ratio of Cash And Equivalents to Revenue for Eiger Biopharmaceuticals is roughly 8.99 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Eiger Biopharmaceutica by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Eiger Revenue vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Eiger Biopharmaceutica |
| = | 141.79 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Eiger Biopharmaceutica |
| = | 15.77 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Eiger Revenue vs Competition
Eiger Biopharmaceuticals is rated # 5 in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 453.7 Million. Eiger Biopharmaceutica holds roughly 15.77 Million in revenue claiming about 3% of equities under Health Care industry.
Eiger Biopharmaceutica Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Eiger Biopharmaceutica, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Eiger Biopharmaceutica will eventually generate negative long term returns. The profitability progress is the general direction of Eiger Biopharmaceutica's change in net profit over the period of time. It can combine multiple indicators of Eiger Biopharmaceutica, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. Eiger Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 51 people.
Eiger Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Eiger Biopharmaceutica. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Eiger Biopharmaceutica position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Eiger Biopharmaceutica's important profitability drivers and their relationship over time.
Use Eiger Biopharmaceutica in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eiger Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eiger Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Eiger Biopharmaceutica Pair Trading
Eiger Biopharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Eiger Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eiger Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eiger Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eiger Biopharmaceuticals to buy it.
The correlation of Eiger Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eiger Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eiger Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eiger Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Eiger Biopharmaceutica position
In addition to having Eiger Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Advertising Thematic Idea Now
Advertising
Companies specializing in advertising, marketing and advertising services. The Advertising theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Advertising Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Eiger Stock
If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |